Stock Search
Search for you Ticker
Find and analyze stocks with comprehensive financial metrics including P/E ratios, dividend yields, and growth indicators. Filter by sector, valuation metrics, and performance to identify investment opportunities.
Company Overview
ELI LILLY & Co
Health CarePharmaceuticalsEli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and U...
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.
Lilly was the first company to mass-produce both the polio vaccine, developed in 1955 by Jonas Salk, and insulin. It was one of the first pharmaceutical companies to produce human insulin using recombinant DNA, including Humulin (insulin medication), Humalog (insulin lispro), and the first approved biosimilar insulin product in the US, Basaglar (insulin glargine). It achieved commercial success with major depressive disorder drugs Prozac (fluoxetine) (1986), Cymbalta (duloxetine) (2004), and its antipsychotic medication Zyprexa (olanzapine) (1996), all of which are now off patent and are manufactured by others as generic drugs. In 2005, Lilly brought exenatide to market—the first of the GLP-1 receptor agonists—followed by the GIP and GLP-1 receptor agonist drugs Mounjaro and Zepbound (tirzepatide).
Exchange: NYSE
Company Statistics
Profile
Market Cap$1.14T
EV$1.18T
Shares Out893.7M
Revenue$79.67B
Margins
Gross83.4%
Operating68%
Pre-Tax42.2%
Net33.5%
Returns (5Yr Avg)
ROA14%
ROE74.9%
ROCE42.6%
ROIC49.3%
Valuation (TTM)
P/E42.5
P/B33.5
EV/Sales14.8
EV/Gross Profit17.8
Financial Health
Cash$8.95B
Net Debt$45.96B
Debt/Equity1.6
Growth (CAGR)
Rev 3Yr31.7%
Rev 5Yr21.6%
Rev 10Yr12.6%
Dil EPS 3Yr49.3%
Dil EPS 5Yr27.6%
Dil EPS 10Yr26.1%
Shares 5Yr-0.3%
Dividends
Yield0.5%
Payout22.4%
DPS$6.69
DPS Growth 3Yr4.7%
DPS Growth 5Yr8.8%
DPS Growth 10Yr9.8%
Price History
No price history available
Financial Performance
Display:
Data reported in USD
Assets vs Liabilities
Data reported in USD
Free Cash Flow
Data reported in USD
No cash flow data available